From SPOP to TP53: How Molecular Markers Shape Treatment Pathways скачать в хорошем качестве

From SPOP to TP53: How Molecular Markers Shape Treatment Pathways

A regional roundtable discussion, moderated by L. Crain Garrot, MD, Georgia Cancer Specialists, focused on the diagnostic and treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Garrot was joined by other Atlanta-based urologists and medical oncologists, including Shailesh Satpute, MD, PhD, Georgia Cancer Specialists; Yasin Bhanji, MD, Georgia Urology; Caroline Lu, MD, Georgia Urology; and Froylan Gonzalez, MD, Georgia Urology. In the fifth segment of the roundtable, the panel weighs the growing role of next-generation sequencing and genetic testing in prostate cancer care, emphasizing how specific mutations like SPOP, TP53, and RB1 help guide treatment decisions. They also break down the rationale behind using triplet therapy—ADT, ARPI, and chemotherapy—in mHSPC, particularly for high-volume or aggressive disease, while noting practical challenges in timing and patient selection.